We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+30.48%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.86B
AUM Growth
+$307M
Cap. Flow
+$139M
Cap. Flow %
7.5%
Top 10 Hldgs %
55.49%
Holding
32
New
3
Increased
14
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
MYGN icon
Myriad Genetics
MYGN
+$73.2M
2
UTHR icon
United Therapeutics
UTHR
+$36.5M
3
NVRO
NEVRO CORP.
NVRO
+$31.5M
4
LMNX
Luminex Corp
LMNX
+$27.9M
5
TBPH icon
Theravance Biopharma
TBPH
+$19.9M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$50.8M
2
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$24.5M
3
VSTM icon
Verastem
VSTM
+$16.7M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$9.87M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$5.62M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCRX icon
1
Pacira BioSciences
PCRX
$1.02B
$180M 9.67%
3,652,134
-101,700
-3% -$4.4M
TVTX icon
2
Travere Therapeutics
TVTX
$5.33B
$112M 6.05%
3,914,182
+70,811
+2% +$2.02M
UTHR icon
3
United Therapeutics
UTHR
$26.3B
$110M 5.94%
862,295
+295,369
+52% +$36.5M
PBYI icon
4
Puma Biotechnology
PBYI
$406M
$106M 5.69%
2,303,455
+214,338
+10% +$10.3M
VNDA icon
5
Vanda Pharmaceuticals
VNDA
$312M
$102M 5.49%
4,443,759
-165,284
-4% -$3.37M
SPPI
6
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$97.9M 5.27%
5,829,878
-1,133,878
-16% -$24.5M
NVRO
7
DELISTED
NEVRO CORP.
NVRO
$82.4M 4.44%
1,446,333
+503,263
+53% +$31.5M
KPTI icon
8
Karyopharm Therapeutics
KPTI
$168M
$82.2M 4.43%
321,805
+4,000
+1% +$1.11M
AMRN
9
Amarin Corp
AMRN
$284M
$80.8M 4.35%
248,433
– –
NUVA
10
DELISTED
NuVasive, Inc.
NUVA
$77.3M 4.16%
1,089,523
-10,000
-0.9% -$636K
MYGN icon
11
Myriad Genetics
MYGN
$530M
$75.7M 4.08%
+1,646,330
New +$73.2M
PACB icon
12
Pacific Biosciences
PACB
$422M
$73.1M 3.94%
13,512,958
+936,956
+7% +$4.02M
LMNX
13
DELISTED
Luminex Corp
LMNX
$71.8M 3.87%
2,369,008
+928,882
+65% +$27.9M
URGN icon
14
UroGen Pharma
URGN
$2B
$71.6M 3.85%
1,515,422
+27,931
+2% +$1.3M
CORT icon
15
Corcept Therapeutics
CORT
$10.2B
$70.6M 3.8%
5,038,874
+410,457
+9% +$5.74M
EXEL icon
16
Exelixis
EXEL
$13.9B
$68.7M 3.7%
3,879,050
+669,850
+21% +$13.1M
VCEL icon
17
Vericel Corp
VCEL
$2.3B
$59M 3.18%
4,168,092
+560,000
+16% +$6.57M
STML
18
DELISTED
Stemline Therapeutics, Inc.
STML
$45.6M 2.46%
2,747,198
– –
OXFD
19
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$39.8M 2.14%
2,449,184
+110,000
+5% +$1.57M
QURE icon
20
uniQure
QURE
$2.68B
$38M 2.05%
1,045,065
– –
VSTM icon
21
Verastem
VSTM
$532M
$37.4M 2.01%
429,519
-167,703
-28% -$16.7M
SVRA icon
22
Savara
SVRA
$1.13B
$34.5M 1.86%
3,093,690
+382,500
+14% +$4.4M
ADMA icon
23
ADMA Biologics
ADMA
$1.92B
$28.2M 1.52%
4,539,295
+290,061
+7% +$1.67M
RARX
24
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$26.3M 1.42%
1,454,761
– –
TBPH icon
25
Theravance Biopharma
TBPH
$874M
$23.9M 1.29%
+731,909
New +$19.9M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Consonance Capital Management held 32 positions worth $1.86B, up 20% from $1.55B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Consonance Capital Management deployed $139M of net new capital in Q3 2018, opening 3 new positions and adding to 14 existing holdings. Its largest new stake was Myriad Genetics: 1,646,330 shares worth $75.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Spectrum Pharmaceuticals Inc, an estimated $24.5M trimmed.

  • Consonance Capital Management's largest Q3 2018 buy was Myriad Genetics: 1,646,330 shares worth $75.7M.
  • Consonance Capital Management added most to United Therapeutics in Q3 2018, an estimated $36.5M increase.
  • Consonance Capital Management's biggest Q3 2018 reduction was Spectrum Pharmaceuticals Inc, cutting an estimated $24.5M.
  • Consonance Capital Management fully exited GW Pharmaceuticals Plc American Depositary Shares in Q3 2018, selling an estimated $50.8M.
  • Consonance Capital Management's ten largest holdings make up 55% of its $1.86B portfolio in Q3 2018.
  • Consonance Capital Management opened 3 new positions and closed 3 in Q3 2018.
  • Consonance Capital Management's portfolio value rose 20% quarter-over-quarter to $1.86B.

Based on Consonance Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.